Real‐world effectiveness and safety of ombitasvir/paritaprevir/ritonavir ± dasabuvir ± ribavirin in hepatitis C: AMBER study
Alimentary Pharmacology & Therapeutics2016Vol. 44(9), pp. 946–956
Citations Over TimeTop 1% of 2016 papers
Robert Flisiak, Ewa Janczewska, Marta Wawrzynowicz‐Syczewska, Jerzy Jaroszewicz, Dorota Zarębska‐Michaluk, Khalil Nazzal, Beata Bolewska, Jolanta Białkowska, Hanna Berak, Katarzyna Fleischer‐Stępniewska, Krzysztof Tomasiewicz, K Karwowska, K. Rostkowska, Anna Piekarska, Olga Tronina, G Madej, Aleksander Garlicki, Mariusz Łucejko, Arkadiusz Pisula, E. Karpińska, Wiesław Kryczka, Alicja Wiercińska‐Drapało, Iwona Mozer‐Lisewska, Maciej Jabłkowski, Andrzej Horban, Brygida Knysz, Magdalena Tudrujek‐Zdunek, Waldemar Halota, Krzysztof Simon
Abstract
The results of our study confirm previous findings. They demonstrate excellent effectiveness and a good safety profile of OBV/PTV/r± DSV±RBV in HCV genotype 1-infected patients treated in the real-world setting.
Related Papers
- → Treatment of hepatitis C: Results in real life(2018)61 cited
- → Pharmacokinetics and safety of co-administered paritaprevir plus ritonavir, ombitasvir, and dasabuvir in hepatic impairment(2015)44 cited
- → New direct-acting antivirals in hepatitis C therapy: a review of sofosbuvir, ledipasvir, daclatasvir, simeprevir, paritaprevir, ombitasvir and dasabuvir(2015)49 cited
- → VIEKIRA PAK (Dasabuvir + Ombitasvir + Paritaprevir + Ritonavir)(2017)1 cited
- → Reply to “Pharmacokinetics in hepatic impairment: Mind the protein binding”(2015)